Safety and survival utcomes of 177 Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate Cancer with prior 223 Ra treatment: the RALU study

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource
Sprache
Englisch

Erschienen in
In: Journal of Nuclear Medicine, 64, 4, S. 574-578

Ereignis
Veröffentlichung
(wo)
Augsburg
(wer)
Universität Augsburg
(wann)
2022
Ereignis
Veröffentlichung
(wo)
New York, NY
(wer)
Society of Nuclear Medicine
(wann)
2022
Urheber
Rahbar, Kambiz
Essler, Markus
Pabst, Kim M.
Eiber, Matthias
Fougère, Christian la
Prasad, Vikas
Rassek, Philipp
Hasa, Ergela
Dittmann, Helmut
Bundschuh, Ralph Alexander
Fendler, Wolfgang P.
Kurtinecz, Milena
Schmall, Anja
Verholen, Frank
Sartor, Oliver

DOI
10.2967/jnumed.122.264456
URN
urn:nbn:de:bvb:384-opus4-1057224
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
25.03.2025, 13:46 MEZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Rahbar, Kambiz
  • Essler, Markus
  • Pabst, Kim M.
  • Eiber, Matthias
  • Fougère, Christian la
  • Prasad, Vikas
  • Rassek, Philipp
  • Hasa, Ergela
  • Dittmann, Helmut
  • Bundschuh, Ralph Alexander
  • Fendler, Wolfgang P.
  • Kurtinecz, Milena
  • Schmall, Anja
  • Verholen, Frank
  • Sartor, Oliver
  • Universität Augsburg
  • Society of Nuclear Medicine

Entstanden

  • 2022

Ähnliche Objekte (12)

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

Treatment with a 177Lutetium-radiolabeled ligand targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer: toxicity, efficacy and survival.

Treatment with a 177Lutetium-radiolabeled ligand targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer: toxicity, efficacy and survival.

Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer

Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer

Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study

Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra : PARABO, a Prospective, Noninterventional Study

Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer

Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer

Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy

Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy

Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement

Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement

Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study

Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy

Verbundene Objekte